Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 2
---
 to 3,536,345 American Depositary Shares Representing 353,634,500,000 Ordinary Shares

Up to 3,536,345 American Depositary Shares Representing 353,634,500,000 Ordinary Shares Underlying the Pre-Funded Warrants

Up to 53,045,175 American Depositary Shares Representing 5,304,517,500,000 Ordinary Shares Underlying the Series L Warrants (which contain a “zero cash exercise price” option)

Up to 2,652,259 American Depositary Shares Representing 265,225,900,000 Ordinary Shares Underlying the Placement Agent Warrants (which contain a “zero cash exercise price” option)

___________________</div>

This
preliminary prospectus, or prospectus, relates to a best efforts public offering of up to
3,536,345 Units, or Units, of Biodexa Pharmaceuticals PLC, a public limited company organized
under the laws of England and Wales, or the Company, each Unit consisting of (i) one American
Depositary Share (representing 100,000 of our ordinary shares, nominal value £0.000001
per share, or Ordinary Shares), or Depositary Shares, and (ii) one Series L warrant, or Series
L Warrant, to purchase one Depositary Share, at an assumed combined public offering price
of $5.09 per Unit, based upon the closing price of our Depositary Shares on the NASDAQ Capital
Market on December 4, 2025, or otherwise acquire such greater number of Depositary Shares
as determined in accordance with the provisions of the Series L Warrant upon a “zero
cash exercise price” option (as discussed below).

Each Series L Warrant will be immediately
exercisable at an exercise price of 225% of the public offering price of each Unit in this offering and will expire two and a half (2.5)
years after the issuance date. The Series L Warrants also contain certain anti-dilution protections, certain mechanisms for cashless exercise
and contain a zero cash exercise price option, as well as certain reset provisions of the exercise price and the number of Depositary
Shares (represented by Ordinary Shares) underlying the Series L Warrants, as further described herein.

Under the “zero cash
exercise price” option of the Series L Warrants, during the period of 90 calendar days following the issue date of the Series L
Warrants, a holder